Hologic, Inc. (HOLX) |
68.87 -0.53 (-0.76%)
|
10-02 16:00 |
Open: |
69.2 |
Pre. Close: |
69.4 |
High:
|
69.32 |
Low:
|
68.09 |
Volume:
|
1,543,922 |
Market Cap:
|
16,869(M) |
|
|
Technical analysis |
as of: 2023-10-02 4:20:41 PM |
Short-term rate:
|
|
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
Mid-term rate:
|
|
Target: |
Six months: 85.91 One year: 89.86 |
Support: |
Support1: 68.08 Support2: 56.65  |
Resistance: |
Resistance1: 73.55 Resistance2: 76.94 |
Pivot: |
70.76  |
Moving Average: |
MA(5): 69.49 MA(20): 71.38 
MA(100): 77.18 MA(250): 77.23  |
MACD: |
MACD(12,26): -1.6 Signal(9): -1.5  |
Stochastic oscillator: |
%K(14,3): 14.2 %D(3): 11.2  |
RSI: |
RSI(14): 28.7  |
52-week: |
High: 87.87 Low: 59.77 |
Average Vol(K): |
3-Month: 1,798 (K) 10-Days: 1,509 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HOLX ] has closed above bottom band by 9.5%. Bollinger Bands are 11.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
69.45 - 69.85 |
69.85 - 70.28 |
Low:
|
66.98 - 67.42 |
67.42 - 67.89 |
Close:
|
68.04 - 68.8 |
68.8 - 69.64 |
|
Company Description |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts. |
Headline News |
Mon, 02 Oct 2023 Bank Julius Baer & Co. Ltd Zurich Raises Holdings in Hologic, Inc ... - MarketBeat
Mon, 02 Oct 2023 Hologic, Inc. Rings the Opening Bell - Nasdaq
Sun, 01 Oct 2023 LaFleur & Godfrey LLC Acquires 6315 Shares of Hologic, Inc ... - MarketBeat
Wed, 27 Sep 2023 Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a ... - Nasdaq
Fri, 22 Sep 2023 Nanaz Mohtashami Elected to Hologic Board of Directors - Hologic, Inc. - Investor Relations
Thu, 21 Sep 2023 Hologic and Bayer Announce International Partnership to Deliver ... - Hologic, Inc. - Investor Relations
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Outperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Outperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Medical Instruments & Supplies |
Shares Out. |
245 (M) |
Shares Float |
242 (M) |
% Held by Insiders
|
0.7 (%) |
% Held by Institutions
|
99.4 (%) |
Shares Short
|
4,660 (K) |
Shares Short P.Month
|
5,330 (K) |
Stock Financials |
EPS
|
1.9 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
21.15 |
Profit Margin (%)
|
11.9 |
Operating Margin (%)
|
23 |
Return on Assets (ttm)
|
6.2 |
Return on Equity (ttm)
|
9.5 |
Qtrly Rev. Growth
|
-1.8 |
Gross Profit (p.s.)
|
13.51 |
Sales Per Share
|
16.49 |
EBITDA (p.s.)
|
5.26 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
961 (M) |
Levered Free Cash Flow
|
736 (M) |
Stock Valuations |
PE Ratio
|
36.05 |
PEG Ratio
|
1.7 |
Price to Book value
|
3.25 |
Price to Sales
|
4.17 |
Price to Cash Flow
|
17.55 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|